Metabolism and Transport of Tamoxifen in Relation to its Effectiveness: New Perspectives on an Ongoing Controversy
- 11 December 2013
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 10 (1) , 107-122
Abstract
Tamoxifen reduces the rate of breast cancer recurrence by approximately a half. Tamoxifen is metabolized to more active metabolites by enzymes encoded by polymorphic genes, including cytochrome P450 2D6 (CYP2D6). Tamoxifen is a substrate for ATP-binding cassette transporter proteins. We review tamoxifen’s clinical pharmacology and use meta-analyses to evaluate the clinical epidemiology studies conducted to date on the association between CYP2D6 inhibition and tamoxifen effectiveness. Our findings indicate that the effect of both drug-induced and/or gene-induced inhibition of CYP2D6 activity is likely to be null or small, or at most moderate in subjects carrying two reduced function alleles. Future research should examine the effect of polymorphisms in genes encoding enzymes in tamoxifen’s complete metabolic pathway, should comprehensively evaluate other biomarkers that affect tamoxifen effectiveness, such as the transport enzymes, and focus on subgroups of patients, such as premenopausal breast ...Keywords
Funding Information
- US National Cancer Institute at the NIH (R01 CA118708)
- Danish Cancer Society (DP06117)
- Danish Medical Research Council (DOK 1158859)
This publication has 110 references indexed in Scilit:
- Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studiesDrug Resistance Updates, 2012
- Discovery of complex pathways from observational dataStatistics in Medicine, 2010
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Genotype-guided tamoxifen therapy: time to pause for reflection?The Lancet Oncology, 2009
- Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohortBreast Cancer Research and Treatment, 2009
- Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopramBritish Journal of Cancer, 2008
- Tamoxifen: Catalyst for the change to targeted therapyEuropean Journal of Cancer, 2008
- Breast cancer recurrence risk in relation to antidepressant use after diagnosisBreast Cancer Research and Treatment, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002